Kadcyla (Ado-trastuzumab emtansine) medicine


Medical Evidence kadcyla

Generic name : Ado-trastuzumab emtansine.

Trade name : Kadcyla.

Manufacturer information :

Kadcyla is manufactured by Genentech, Inc.

Kadcyla FDA Approval :

Kadcyla first approved February 22nd, 2013.

Kadcyla Dosage form :

Lyophilized powder in single-use vials containing 100 mg per vial or 160 mg

per vial.

Kadcyla Indications and Usage :

Metastatic Breast Cancer

Indicated as a single agent for treatment of HER2-positive, metastatic breast cancer in patients who previously received trastuzumab and a taxane, separately or in combination.

Kadcyla (Ado-trastuzumab emtansine) availability in India

  • You could import this medicine against import permit on Patient Name.
  • Please contact ACT Lifesciences Private Limited for further information.